Avatrombopag, an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist, is currently in clinical development for the potential treatment of severe thrombocytopenia in patients with chronic liver disease undergoing an elective procedure. The objectives of this study were to characterize and compare the pharmacokinetics (including the food effect) and pharmacodynamics (platelet count) of avatrombopag following single doses in Japanese and white subjects. Following single dosing under fasted and fed conditions, mean peak concentrations occurred at 5 to 8 hours and subsequently declined with a half-life of 16 to 18 hours in Japanese and white subjects. Administration with food did not alter the rate or extent of avatrombopag absorption but substantially reduced pharmacokinetic variability relative to the fasted state. CYP2C9 polymorphism (*2, *3) was associated with higher pharmacokinetic variability but not with any clinically important effect on variability in platelet response. Plasma exposures of avatrombopag increased in a doseproportional manner over the dose range tested. After a single dose, platelet count increased in a dose-related manner, reaching a maximum by day 11 and returning to baseline levels by day 27. No clinically important differences were found when avatrombopag pharmacokinetics and pharmacodynamics were compared between Japanese and white subjects. Administration of avatrombopag was generally well tolerated.
A previous study of avatrombopag oral suspension in healthy volunteers demonstrated dose-dependent increases in platelet count following single doses of up to 75 mg and after 20-mg once-daily doses administered for 10 days. Avatrombopag was shown to be well tolerated in this study. 7 In a radiolabeled human mass balance study, avatrombopag and its metabolites were eliminated in feces (88%) and urine (6%).
Approximately 34% and 44% of the dose was unchanged drug and its 4-hydroxy metabolite in feces, respectively. Avatrombopag is primarily metabolized in the liver, with cytochrome P450 (CYP) 2C9 and CYP3A contributing to the formation of 4-hydroxy avatrombopag as determined by in vitro studies using human liver microsomes and recombinant human CYP isoforms.
Thrombocytopenia, a potentially serious condition characterized by a deficiency of platelets in the circulatory system, occurs both in association with a variety of diseases and as a consequence of druginduced immunologic destruction. Platelet transfusion is the only treatment option for patients with severe thrombocytopenia associated with chronic liver disease; however, transfusion-related complications such as febrile reactions, the risk of transmission of infectious agents, and the likelihood of alloimmunization has remained. Convenient, effective, and safe alternatives to platelet transfusions would be considered beneficial to patients. 8 Ethnicity has been shown to influence the pharmacokinetics (PK) of some drugs and/or their pharmacodynamics (PD). This may result in variability in drug response between ethnic groups and hence specific dosing recommendations by ethnicity. 9 Therefore, the investigation of potential racial differences is important to support appropriate clinical use. Furthermore, such data may be used to assess the acceptability of foreign clinical data in supporting regional drug development requirements, enabling extrapolation of foreign clinical data to the new region and/or multiregional clinical development. 10 The objectives of this study were to characterize and compare the PK (including the food effect), the PD (platelet count), the effect of CYP2C9 polymorphism (CYP2C9*2, *3), and the safety and tolerability following a single (20-, 40-, or 60-mg) dose of avatrombopag between healthy Japanese and white subjects, using the to-be-marketed formulation (20-mg tablet).
Methods

Study Design
This was a randomized, open-label, 5-treatmentperiod, single-dose study (Clinical Trials.gov identifier NCT02039076) to assess the PK and PD of avatrombopag and to explore the effects of ethnicity. The doseproportionality of PK, the effect of food on exposure, the influence of pharmacogenomics, and the safety and tolerability were compared between Japanese and white subjects. Dosing consisted of a single oral dose of 40 or 60 mg under fasted and fed conditions or 20 mg under fed conditions. Subjects were randomly assigned 1:1:1:1 stratified by ethnicity to 1 of 4 treatment periods (sequences A to D) ( Table 1 ). The washout period of 28 days or longer was set between the administration of avatrombopag in each period.
This study was conducted in a total of 24 healthy Japanese subjects and 24 healthy white subjects at a single center (California Clinical Trials Medical Group, Glendale, California) in the United States, according to the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol was approved by the Institutional Review Board (IntegReview Ethical Review Board, Austin, Texas), and informed consent for all participants was obtained prior to screening.
Subjects
Healthy male and female Japanese or white subjects aged 20 to 55 years with body mass index from 18 to 28 kg/m 2 were included in this study. Japanese subjects were defined as having been born in Japan of Japanese parents and grandparents, living outside of Japan for <5 years, and keeping their Japanese lifestyle, habits, and diet. Females were required to have negative serum β-human chorionic gonadotropin test results or negative urine pregnancy test results at screening and baseline. Females of child-bearing potential also had to agree to use a medically acceptable method of contraception throughout the entire study period and for 30 days after study drug discontinuation. Subjects were excluded from this study if their platelet counts were less than the limit of normal or more than 350 × 10 9 /L at the time of screening and at each baseline assessment.
Study Drug Formulation and Administration
The study drug was provided as a tablet containing 20 mg of avatrombopag (1-
carbamoyl}-2-pyridyl) piperidine-4-caboxylic acid monomaleate) by Eisai Co, Ltd. Subjects were hospitalized from the day before dosing (day -1) to day 2. Under fasted conditions, subjects were administered study drug following an overnight fast of at least 10 hours with 240 mL of water. Subjects were not allowed any food for at least 4 hours after dosing. Under fed conditions, subjects started taking a high-fat meal (approximately 800 to 1000 kcal, with at least 50% calories derived from fat) 30 minutes before the time to receive the study drug. The subjects were required to finish the meal within 30 minutes. Subjects were administered study drug with 240 mL of water at 30 minutes after the start of the meal. Subjects were not allowed any additional food for a period of 4 hours after dosing.
Pharmacokinetic Assessment
Blood samples for measuring plasma avatrombopag concentration were collected predose and 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72 , and 96 hours after dosing in each treatment period. Plasma was separated by centrifugation at 3000 rpm for 10 minutes at 4°C. The plasma samples were stored in polypropylene tubes at approximately -20°C until analysis. The plasma concentrations of avatrombopag were quantified using a validated liquid chromatography-tandem mass spectrometry assay at XenoBiotic Laboratories, Inc (Plainsboro, New Jersey). The method utilized a protein precipitation 10 ) from 100 μL of human plasma. The liquid chromatography-tandem mass spectrometry analysis was carried out with a Sciex API-4000 coupled with a Shimadzu LC system. The chromatographic separation was achieved on a HPLC reversed-phase Luna C8, 5 μm, 50 × 2.0 mm column with a mobile phase gradient using 10 mM ammonium formate in water, pH 4, and methanol:acetonitrile (1:1). The mass spectrometer was operated in positive electrospray ionization mode, and the resolution used was set for both Q1 and Q3. The multiple reaction monitoring transition was m/z 649.2 → 267.1 for avatrombopag and m/z 659.4 → 267.1 for the internal standard. The interrun accuracy and interrun precision met acceptance criteria and were within ±15%. The intrarun accuracy and precision of the lower limit of quantitation samples met acceptance criteria and were within ±20% of the lower limit of quantitation at 1.00 ng/mL. The calibration curve ranged from 1.00 ng/mL to 500 ng/mL for avatrombopag. Noncompartmental PK analysis was performed to derive PK parameters of avatrombopag in plasma using Phoenix WinNonlin software (Pharsight, Mountain View, California). PK parameters included the maximum observed plasma concentration (C max ), time at which the highest drug concentration occurs (t max ), the area under the plasma concentration-time curve from 0 time to time of last quantifiable concentration (AUC (0-t) ), the area under the plasma concentrationtime curve from 0 time to time extrapolated to infinity (AUC (0-inf) ), and the terminal elimination phase plasma half-life.
Pharmacodynamic Assessment
Blood samples for determination of platelet count (normal range: approximately 150 to 400 × 10 9 /L) for PD were collected predose and on days 5, 8, 11, 14, 21, 24, and 28 of each treatment period. The change from baseline in platelet count for each time point after avatrombopag dosing was estimated. Noncompartmental analysis for drug effect was performed to derive PD parameters of avatrombopag in plasma using Phoenix WinNonlin software. PD parameters included the observed time of maximum increase in platelet count following avatrombopag dosing in each treatment (TE max ), the maximum increase in platelet counts following avatrombopag dosing observed in each treatment (E max ), and the area under the effect curve for platelet count following avatrombopag dosing (day 1 in each treatment) through 28 days after dosing (day 28 in each treatment) (AUEC (0-28d) ).
Genotyping Procedures for CYP2C9
CYP2C9 genotyping was conducted by Cancer Genetics Inc, (formerly Gentris; Rutherford, New Jersey) using a sequencing method. Genomic DNA was isolated using a Promega (Madison, Wisconsin) kit. Proprietary primers were used to amplify the region of interest. Amplified DNA was sequenced using Applied Biosystems (Foster City, California) big dye terminator sequencing kit and analyzed on an ABI 3730 XL genetic analyzer. The resulting Sanger sequencing data pertaining to the relevant CYP2C9 alleles were obtained. Subjects having either the *2 or *3 allele (*1/*2 or *1/*3) were defined as hetero intermediate metabolizers.
Safety Assessments
Safety data that were evaluated included all adverse events, clinical laboratory results, vital signs (diastolic and systolic blood pressure, pulse rate, respiration rate, and temperature), and 12-lead electrocardiograms.
Statistical Analysis
It was considered that a sample size of 22 subjects in each ethnic group should be adequate for each dose to assess similarity of exposure based on the intersubject variability of previous bioavailability studies in healthy subjects. Comparison between Japanese subjects (test) and white subjects (reference) at doses of 40 and 60 mg was made by estimating the percentage of geometric least-squares mean (Japanese/white) and 90%CIs. Considering PK variability, it was determined that we may conclude that PK was similar between Japanese and white subjects if the percentage of geometric leastsquares mean was within 0.77 and 1.3. Dose proportionality was evaluated using a power model to assess the slope parameter and 95%CIs using the equation log(Y) = α+ βlog(X), where X is dose and Y is C max or AUC. Dose proportionality was concluded if the slope was contained within the interval of 0.7 to 1.3.
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Food effect was assessed using ratios of PK parameters (fed/fasted) of the geometric least-squares mean and 90%CIs for PK parameters using a mixed-effect model. Safety data were summarized by dose under fasted and fed conditions using descriptive statistics. All statistical programming and analyses were performed using SAS software, version 9.2 (SAS Institute, Inc, Cary, North Carolina).
Results
Demographics and Disposition
Forty-eight healthy subjects were enrolled and randomized, 36 of whom (18 subjects in each ethnic group) completed all planned study procedures. The baseline demographics of the study participants are summarized in Table 2 . The mean weight and height of the Japanese subjects were slightly lower than those of the white subjects (mean weight 62 kg and 70 kg, mean height 165 cm and 170 cm, respectively), but there were no other notable differences between Japanese and white subjects in demographic characteristics. Among the 12 subjects who discontinued the study, 3 subjects were discontinued due to noncompliance, 7 subjects withdrew consent, 1 subject was discontinued due to an adverse event of influenza-like illness, and 1 subject was discontinued due to a decrease in pulse rate (60 mg fed conditions).
Pharmacokinetic Results
Mean (+ standard error) plasma avatrombopag concentration-time profiles under fed conditions by ethnic group are presented in Figure 1 . Corresponding PK parameters are summarized in Table 3 . Following single-dose administration of 20, 40, and 60 mg, avatrombopag under fed conditions attained maximum concentrations at approximately 6 to 8 hours after dosing in both Japanese and white subjects. Mean terminal half-time values were approximately similar in Japanese and whites, ranging from 16 to 17 hours in Japanese and from 18 to 19 hours in white subjects. Avatrombopag C max at 40-and 60-mg doses in Japanese subjects was slightly higher than that in white subjects. The percentages of geometric least-squares mean (Japanese/white) for C max indicate that Japanese C max values are ß29% higher than those of whites, and the 90%CIs of percentage ratios did not contain 1.00. Meanwhile, AUC (0-inf) values were similar in both ethnic groups at 40-and 60-mg doses, and percentage ratios of Japanese to whites (90%CIs) for AUC (0-inf) were 108% (89.1% to 131%), 104% (85.7% to 127%), respectively (Table 4) . Mean avatrombopag C max and AUC values each increased in a dose-proportional manner following singledose administration of 20, 40, and 60 mg for both ethnic groups under fed condition. Estimates of slopes were in all cases close to 1.00, and the corresponding 95%CIs all contained 1.00, indicating that the avatrombopag C max and AUC increased proportionally with dose.
Consumption of a high-fat meal was associated with reduced intrasubject and intersubject variability of avatrombopag PK (Table 5 ). Geometric least-squares mean values at 40-and 60-mg doses comparing the fed and fasted administrations were 83.9% and 96.2% for C max , 91.9% and 108% for AUC (0-inf) in Japanese subjects. Geometric least-squares mean values at 40-and 60-mg doses comparing the fed and fasted administrations were 132% and 144% for C max , 156% and 180% for AUC (0-inf) in white subjects. The 90%CIs of neither percentrage ratio met the bioequivalence criteria due to large variability of PK parameters, especially under %Ratio indicates Fed/Reference × 100. AUC (0-inf) , area under the concentration-time curve from time 0 to infinity; C max , maximum drug concentration; LS, least-squares; t max , time to reach maximum concentration after drug administration; %CV, coefficient of variation.
fasted conditions. Coadministration with a high-fat meal did not affect t max of avatrombopag in either ethnic group administered single 40-or 60-mg doses.
Pharmacodynamic Results
Platelet Count. Increases in platelet count following single doses of avatrombopag were observed at 20-to 60-mg doses. Platelet counts generally increased to a maximum mean change from baseline of approximately 50 to 110 × 10 9 /L on days 8 to 11, then decreased to approximate baseline levels by the end of the treatment period (day 28) as illustrated in Figure 2 . Although characterized by relatively high variability, the response of platelet count was similar between ethnic groups. The PD parameters were comparable between Japanese and white subjects under fed conditions (Table 6 ). Across all treatments and ethnic groups, the median observed time of maximum increase in platelet count was 8 to 11 hours. Only 1 white subject in each cohort administered 40 and 60 mg fed had a maximum increase in platelet counts >500 × 10 9 /L. The systemic exposure to avatrombopag appeared to be correlated with area under the effect curve for platelet count over 28 days of treatment.
Pharmacogenomics of CYP2C9
CYP2C9 genotype was studied in 24 subjects in each ethnic group. For the hetero intermediate metabolizers CYP2C9 (*1/*2) genotype, there were 7 (29.2%) determined in the white group and 1 (4.2%) in the Japanese group. For the hetero intermediate metabolizers CYP2C9 (*1/*3) genotype, 2 (8.3%) white subjects were identified, and none in the Japanese group. Figure  3 shows the relationship between dose and AUC (0-inf) of avatrombopag (panel A) and between dose and maximum change from baseline in platelet count (panel B) with respect to CYP2C9 genotypes. On examination of the PK data, a few subjects who had mutant allele(s) of CYP2C9 (*1/*2, *1/*3; intermediate metabolizer) had higher exposures, and these outliers were predominantly CYP2C9*1/*3 genotype. On the other hand, PD effects were not affected by such PK outliers, and the maximum platelet count change from baseline in intermediate metabolizers completely overlapped with those in subjects without mutant allele(s).
Safety Results
Treatment-emergent adverse events (TEAEs) in the avatrombopag treatment group were reported by 10 out of 24 Japanese subjects (41.7%) and 5 out of 24 white subjects (20.8%). The overall incidence of TEAEs was not dose dependent across study treatments in Japanese subjects. The treatment-related TEAE was seen in 1 of 24 Japanese subjects and 4 of 24 white subjects. All TEAEs were mild except for influenza-like illness. One white subject was discontinued due to the moderate TEAE of influenza-like illness. Headache was the most frequently reported TEAE (n = 3 in Japanese, n = 7 in whites). There were no deaths or serious TEAEs reported during the study. There were no clinically relevant changes in electrocardiographic parameters (including QTcF), laboratory parameters, physical examination findings, or vital signs.
Discussion
Avatrombopag is currently in late-stage clinical development for the potential indication of severe This clinical pharmacology study of avatrombopag was a PK and PD bridging study to enable enrollment of patients from Japan in the phase 3 studies. The study successfully demonstrated no clinically important differences between Japanese and white subjects in PK, platelet response, or safety and tolerability at doses used in phase 3 studies, 40 and 60 mg. The 20-mg dose also utilized in the current study was introduced primarily for PK dose-proportionality evaluation, thus, the ethnic comparison did not include the 20-mg data. Furthermore, in Japanese subjects, avatrombopag exhibited dose-proportional PK for doses ranging from 20 to 60 mg and a notable decrease of inter-and intrasubject variability (ß28%) in plasma avatrombopag exposure without any impact on rate or extent of absorption following dosing with food relative to fasted state.
The absorption of avatrombopag after oral administration is relatively slow, with peak plasma avatrombopag concentrations observed at approximately 5 to 8 hours after single-dose administration. Avatrombopag is characterized by poor aqueous solubility, and the slow absorption rate may reflect solubility-rate-limited absorption. Importantly, poor solubility did not impact the extent of drug absorption across the range of doses tested, as evidenced by confirmation of dose proportionality in C max and AUC for doses ranging from 20 to 60 mg.
The avatrombopag plasma exposures after single dosing under fasted condition were characterized by high intersubject variability, with coefficient of variation (CV%) of approximately 46.1% to 60.8%. The intersubject variability was substantially reduced under fed conditions, which ranged from approximately 23.7% to 30% CV% in Japanese or approximately 38.2% to 62.3% CV% in whites. The intrasubject variability under fed conditions was also reduced to approximately 18% to 20% derived from previous bioavailability study data in healthy subjects. Interestingly, food affected only the variability in the derived PK parameters without influencing the rate or extent of absorption, as shown by the lack of an effect of food on mean values of C max , AUC, and t max . These results could be explained by food potentially prolonging gastrointestinal transit and thus allowing greater uniformity of solubility of avatrombopag, thereby reducing variability in absorption. Based on this result, avatrombopag is administered under fed conditions in phase 3 trials.
In vitro data using human liver microsomes and recombinant human CYP isoforms have shown that CYP2C9 and CYP3A are the primary routes of metabolism of avatrombopag. CYP2C9 is well known to have polymorphism and to effect decrease of enzyme activity. CYP2C9*2 (C430T) and CYP2C9*3 (A1075C) exhibit largely reduced catalytic activity in a substratedependent manner. The intermediate metabolizer phenotype due to CYP2C9 polymorphism is more common in whites relative to the Asian population. 12 Allele frequencies are approximately 11% (*2) and 7% (*3) in white subjects, and 0% (*2) and 3% (*3) in Asian subjects. Therefore, the relationship of the PK of avatrombopag with CYP2C9 genotype was explored in this study. There was a substantial overlap when we compared PK parameters between subjects with and without CYP2C9 polymorphisms (*1/*2, *1/*3). However, several subjects with CYP2C9 polymorphisms had relatively high PK exposure. These polymorphisms (CYP2C9*1/*2, CYP2C9*1/*3) may result in a decrease in the clearance of avatrombopag and thus an increase in plasma exposure and also may contribute to the PK variability of avatrombopag.
Avatrombopag increased platelet count in a dosedependent manner. After single doses, platelet count reached a maximum by 11 days postdose and then returned to baseline level by 27 days postdose. This delayed response of platelet count is predicted from the hypothesized mechanism of action for avatrombopag, which acts on the TPO receptor concurrently with endogenous TPO and differentiation into megakaryocytes, and thereby increases the number of circulating platelets. Given this delay in PD response and the known natural fluctuation of platelet count during the day, small variations in PK generally have no significant influence on platelet response. The extent of the observed increase in platelet count is similar to a study of avatrombopag suspension in healthy volunteers in a previous publication. 7 The safety analysis showed that avatrombopag was generally well tolerated in healthy volunteers administrated 20 to 60 mg as a single dose. The overall incidence of TEAEs did not increase with increasing doses and was similar in each dose group.
Conclusion
Avatrombopag showed dose-proportional increase in PK and platelet count in healthy subjects. The PK and PD of avatrombopag were similar between Japanese and white subjects, thus enabling the possibility of simultaneous global clinical development, which may lead to faster access for the patients who need these new products.
